Literature DB >> 21423257

Hematology: Setting the standard for newly diagnosed multiple myeloma.

Jacob Laubach, Paul G Richardson, Kenneth Anderson.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21423257     DOI： 10.1038/nrclinonc.2011.43

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Vassiliki Poulaki; Yu-Tzu Tai; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Robert Schlossman; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

Review 2.  Ten years of improvement in the management of multiple myeloma: 2000-2010.

Authors:  Jean-Luc Harousseau
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-12

Review 3.  Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.

Authors:  Asher A Chanan-Khan; Sergio Giralt
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

4.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Authors:  Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David E Avigan; Wanling Xie; Irene M Ghobrial; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

5.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

6.  Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

Authors:  Jean-Luc Harousseau; Michel Attal; Hervé Avet-Loiseau; Gerald Marit; Denis Caillot; Mohamad Mohty; Pascal Lenain; Cyrille Hulin; Thierry Facon; Philippe Casassus; Mauricette Michallet; Hervé Maisonneuve; Lotfi Benboubker; Frédéric Maloisel; Marie-Odile Petillon; Iain Webb; Claire Mathiot; Philippe Moreau
Journal:  J Clin Oncol       Date:  2010-09-07       Impact factor: 44.544

7.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Authors:  M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

8.  Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.

Authors:  S Vincent Rajkumar; Laura Rosiñol; Mohamad Hussein; John Catalano; Wieslaw Jedrzejczak; Lela Lucy; Marta Olesnyckyj; Zhinuan Yu; Robert Knight; Jerome B Zeldis; Joan Bladé
Journal:  J Clin Oncol       Date:  2008-03-24       Impact factor: 44.544

9.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors:  S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal:  Lancet Oncol       Date:  2009-10-21       Impact factor: 41.316

10.  Single versus double autologous stem-cell transplantation for multiple myeloma.

Authors:  Michel Attal; Jean-Luc Harousseau; Thierry Facon; François Guilhot; Chantal Doyen; Jean-Gabriel Fuzibet; Mathieu Monconduit; Cyrille Hulin; Denis Caillot; Reda Bouabdallah; Laurent Voillat; Jean-Jacques Sotto; Bernard Grosbois; Regis Bataille
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.